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Abstract
Background: Medication-overuse headache (MOH) is a chronic disorder that results from the overuse of analgesics
drugs, triptans or other acute headache compounds. Although the exact mechanisms underlying MOH remain still
unknown, several studies suggest that it may be associated with development of “central sensitization”, which may
cause cutaneous allodynia (CA). Furthermore, the epidemiology of drug-induced disorders suggests that medication
overuse could lead to nephrotoxicity. The aim of this work was to confirm and validate the results obtained from
previous proteomics studies, in which we analyzed the urinary proteome of MOH patients in comparison with
healthy non-abusers individuals.
Methods: MOH patients were divided into groups on the basis of the drug abused: triptans, non-steroidal
anti-inflammatory drugs (NSAIDs) and mixtures, (mainly containing indomethacin, paracetamol and, in some cases,
caffeine). Healthy subjects, with a history of normal renal function, were used as controls. In this study, four proteins
that were found differentially expressed in urine, and, on the basis of the literature review, resulted related to
kidney diseases, were verified by Western Blot and Enzyme-linked Immunosorbent Assay (ELISA); Prostaglandin-H2
D-synthase (PTGDS), uromodulin (UROM), alpha-1-microglobulin (AMBP) and cystatin-C (CYSC).
Results: Western blot analysis allowed to validate our previous proteomics data, confirming that all MOH patients
groups show a significant over-excretion of urinary PTGDS, UROM, AMBP and CYSC (excluding triptans group for
this latter), in comparison with controls. Moreover, the expression of PTGDS was further evaluated by ELISA. Also
by this assay, a significant increase of PTGDS was observed in all MOH abusers, according to 2-DE and Western
blot results.
Conclusions: In this study, we confirmed previous findings concerning urinary proteins alterations in MOH
patients, identified and demonstrated the over-expression of PTGDS, UROM, AMBP, and CYSC, particularly in
NSAIDs and mixtures abusers. Over-expression of these proteins have been related to renal dysfunction and
probably, PTGDS, to the development of CA. The detection and confirmation of this proteins pattern represent a
promising tool for a better understanding of potential nephrotoxicity induced by drugs overuse and may enhance
awareness related to the MOH-associated risks, even in absence of clinical symptoms.
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Background
A specific condition observed in chronic migraine pa-
tients, classified as medication-overuse headache (MOH)
and characterized by the frequent intake of antimigraine
drugs, is assumed to increase the frequency and intensity
of headache [1]. MOH may complicate every type of head-
ache and, in principle, all acute drugs used for headache
treatment could cause MOH (i.e. ergotamine derivatives,
triptans, simple and combined analgesics, barbiturates and
opioids) [2]. Although the specific mechanisms leading to
MOH remain still unknown, several studies suggest that
MOH may involve amplification processes, including
descending facilitation and “central sensitization”, and an
increased excitability of spinal and medullary dorsal horn
neurons resulting from a continuous input exerted by C-
fiber nociceptors [3, 4]. This may lead to cutaneous
allodynia (CA), a neurologic condition characterized by
touch-evoked pain, elicited through ordinary non-
nociceptive stimulation of the skin [5]. As a marker of
central sensitization, allodynia has been proposed as a
risk factor for progression to chronic migraine [6].
Recently, the development of MOH has been associated
with long-lasting adaptive changes that occur within the
peripheral and central nervous system. Preclinical studies
have shown that repeated or continuous treatment with
antimigraine drugs result in persistent up-regulation of
neurotransmitters within the orofacial division of the
trigeminal ganglia and in the development of CA in
response to migraine triggers, even weeks after discon-
tinuation of the antimigraine drug [7]. In our previous
study we found elevated urinary levels of Prostaglandin-
H2 D-synthase (PTGDS) in 3 MOH patient groups (trip-
tans, NSAIDs and mixture abusers) in respect to healthy
non-abusers individuals as control group [8]. Prostaglan-
din D2 is the most abundant prostanoid produced in the
central nervous system of mammals, and is implicated in
the modulation of neural functions, such as sleep induc-
tion, regulation of body temperature, nociception, pain
responses and allodynia [9]. Some studies with animal
models have demonstrated that prostaglandins play piv-
otal roles in central sensitization at spinal level, resulting
in induction of hyperalgesia and CA (touch-evoked pain)
[10]. Furthermore, elevated levels of PTGDS have been
found in the serum of patients with renal impairment, so
that the protein has even been suggested as a possible
biochemical marker of renal insufficiency [11]. Therefore,
PTGDS might contribute not only to the induction of
allodynia [12], but also to the progression of chronic renal
failure [13]. Based on the important functions assigned
to PTGDS, the purpose of this study was the urinary
quantification and validation in MOH abusers previ-
ously analyzed, by Western blotting and Enzyme-linked
Immunosorbent Assay (ELISA). Moreover, in our previ-
ous works [8, 14] we identified, besides PTGDS, other
proteins as potential biomarkers of nephrotoxicity, includ-
ing Uromodulin (UROM), Alpha-1-microglobulin (AMBP)
and Cystatin-C (CYTC). In recent years, proteomic re-
searches have revealed numerous proteins as candidate
biomarkers, but the lack of protein validation has repre-
sented a weakness for their application into clinical prac-
tice. The main purpose of the present work was to confirm
and validate, by molecular biology techniques, proteins
identified in earlier studies of our research group.
Methods
Subjects
Urine samples were taken from MOH patients, divided
in 3 subgroups: triptans, NSAIDs and mixtures abusers.
Moreover, urine of healthy non-abusers volunteers were
collected and used as control. All patients groups and
controls were matched for age and gender, and each
subject gave informed consent to the study. Urinary
routine parameters were measured in the clinical labora-
tory and resulted in the normal range. The exclusion cri-
teria were renal insufficiency or kidney damage, ischemic
heart disease, autoimmune disorders, oncologic or neuro-
logic syndrome. The study received approval of the Ethical
Committee of the University Hospital of Modena and was
carried out in conformity with the Helsinki Declaration.
Urine sample preparation
The second urine in the morning were collected into a
sterile tube and centrifuged at 800 x g for 10 min at 4 °C,
in order to remove cellular debris and contaminants.
Then, urine samples were concentrated and desalted using
filter devices with a 3 kDa MW cut-off (Millipore). The
final total protein concentration was calculated by the
Bradford method [15], using BSA as standard and rehy-
dration buffer as blank.
SDS-PAGE and two-dimensional gel electrophoresis
Sodium dodecyl sulphate-polyacrylamide gel electrophor-
esis (SDS-PAGE) was performed according to Laemmli’s
procedure under reducing conditions, as previously re-
ported [14]. In brief, 5 μg of total urine proteins for each
group were mixed with the Laemmli sample buffer with
the addition of β-mercaptoethanol as reducing agent.
Samples were then boiled at 95 °C for 5 min and subse-
quently loaded onto 12 % SDS polyacrylamide gel. At
the end of the electrophoresis run, gel were stained with
Coomassie Blue G-250. Urine samples were also sub-
jected to two-dimensional gel electrophoresis (2-DE)
analysis, as previously described [8]. Briefly, 100 μg of
total protein were subjected to first dimension separ-
ation (isoelectric focusing) using 17 cm IPG strip pH
range 3-10 (Ready Strip™, Bio-Rad). Later, the second di-
mension separation was performed employing 8-16 %
polyacrylamide gradient gel and the spot were visualized
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with silver nitrate staining protocol [16]. All gel images
were acquired by a calibrated densitometer (GS800,
Bio-Rad) and both the bands and the spot of interest
were excised and stored at -20 °C until mass spectrom-
etry (MS) analysis.
Mass spectrometry protein identification
Protein bands and protein spot were “in-gel” digested as
previously reported [17]. Briefly, they were first subjected
to a step of de-staining (with acetonitrile for protein bands
and with a solution of potassium hexacyano-ferrate(III)/
sodium thiosulphate for protein spot, respectively). In the
next step, both samples were reduced with dithiotreitol
and alkylated with iodoacetamide, followed by trypsin di-
gestion at 37 °C overnight. The obtained peptides were
extracted by a two-phase procedure, first with aceto-
nitrile/ammonium bicarbonate and then using formic
acid. Finally, the pooled peptides were concentrated in a
vacuum dryer before MS analysis by a Nano LC-CHIP-
MS system, composed of the 6520 ESI-Q-ToF coupled
with a Nano HPLC-Chip microfluidic device (Agilent
Technologies Inc., CA, USA), as previously described in
detail [17]. The MASCOT search engine (version 2.4) was
used for peptide sequence searching against the UniProt
database, setting the following restrictions: Homo sapiens
taxonomy (Human), parent ion tolerance ±20 ppm, MS/
MS error tolerance ±0.1 Da, alkylation of cysteine residues
(fixed modifications), oxidation of methionine (variable
modifications), and two potentially missed trypsin cleav-
ages. The highest score hits among MASCOT search
results were selected. Protein identification was repeated
at least once, using band/spot cut from replicated gel.
Western blotting analysis
A total of 1.5 μg urine proteins were separated on 12 %
SDS-PAGE and blotted onto nitrocellulose membranes,
that were first blocked with 5 % non-fat milk and subse-
quently incubated overnight at 4 °C with the following
primary antibodies (all from Abcam, Cambridge, UK):
anti-Prostaglandin D Synthase (rabbit polyclonal, 1:500);
anti-Uromucoid (rabbit polyclonal, 1:500); anti-Alpha-1-
microglobulin (rabbit monoclonal, 1:1000); anti-Cystatin
C (rabbit monoclonal, 1:500). Membranes were then in-
cubated with a solution containing 1:2000 dilution of
horseradish peroxidase (HRP)-conjugated goat anti-
rabbit secondary antibody (DakoCytomation, Denmark).
Target bands were visualized using a mix of peroxidase so-
lution plus a luminol enhancer solution (WesternSure™
PREMIUM Chemiluminescent substrate). Results acquisi-
tion and band densitometric analysis (represented by arbi-
trary units, AU), were performed using the C-DiGit® Blot
Scanner (LI-COR Biosciences, NE, USA) and the Quanti-
tyOne image analysis software (Bio-Rad). Human serum
sample was used as positive (or negative) control.
Measurement of PTGDS by ELISA
Immunoreactive PTGDS was determined by ELISA
using a commercially available kit (BioVendor, NC,
USA), on the basis of the manufacturer’s instructions.
Briefly, urine samples were diluted 100-fold with dilution
buffer and then incubated for 1 h at room temperature
with polyclonal anti-human L-PTGDS antibody immobi-
lized to the surface of the plate wells. After three wash,
100 mL of conjugate solution (anti-PTGDS conjugated
with horseradish peroxidase, HRP) were added and the
plate incubated for 1 h at room temperature. Following
3 washing steps, the remaining HRP conjugate was
allowed to react with the substrate solution (tetra-
methylbenzidine). Finally, the reaction was stopped by
the addition of acidic solution and absorbance of the
resulting yellow product was measured at λ 450 and
620 nm, using a microplate reader (Multiscan FC,
Thermo Scientific, MA, USA). PTGDS concentrations
were determined from a standard curve generated by
the standards supplied with the kit.
Data analysis
A statistical analysis of ELISA results (for urinary
PTGDS), and of Western blot signal values (obtained from
all proteins tested in each different group), was done with
the Student t-test. A p-value <0.05 was considered as
statistically significant. All data reported in Figs. 3 and 4
are provided as mean ± standard deviation (SD).
Results
SDS-PAGE, 2-DE and image analysis
Urine proteins were first separated according to their
molecular weight by SDS-PAGE (Fig. 1) and gel images
were acquired by a calibrated densitometer (GS800,
Bio-Rad). The bands enclosed in rectangles were cut
from each lane (corresponding to every group of pa-
tients and controls) and were subjected to MS analysis.
As evident in Fig. 1, the result was the identification of
the following proteins: UROM, expressed as a very
intense band in all MOH patients (lane 2 = triptans, lane
3 = NSAIDs and lane 4 =mixtures abusers) respect to
controls (lane 1); AMBP, particularly evident in NSAIDs
group; PTGDS, an intensive band visible in NSAIDs
and mixtures groups, which was much less observable
in triptans abusers and even more in controls, and
CYTC, with a perceptible band in NSAIDs group. To
strengthen these results, we analyzed the same samples
by 2-DE. Isolated and magnified differentially expressed
spots obtained from 2D gels are reported in Fig. 2. The
results overlapped those obtained by SDS-PAGE. In fact,
analyzing the spot staining intensity by the PDQuest image
analysis software (version 7.3.1, Bio-Rad), PTGDS was
significantly over-excreted in NSAIDs (A3), mixtures (A4)
and triptans groups (A2) in comparison to controls (A1);
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UROM resulted over-expressed in triptans (B2), NSAIDs
(B3) and mixtures abusers (B4), compared to controls (B1);
AMBP spots were significantly increased only in NSAIDs
(C3) and mixtures abusers (C4) respect to triptans (C2) and
controls (C1); finally, CYTC resulted particularly elevated
in NSAIDs abusers (D3). Furthermore, we illustrated the
3D views of PTGDS protein spot, developed with the
PDQuest software, in order to provide a clearer vision of its
expression change in the examined groups.
MS protein identification
MS analysis was performed using an Electrospray-
Quadrupole-Time of Flight (ESI-Q-ToF) mass spec-
trometer (Agilent Technologies, CA, USA). Protein
identification was achieved using the Agilent MassHunter
Workstation software (version B.02.00) and the search
was conducted by MASCOT search engine (version 2.4)
against the UniProt database. During MASCOT search,
the significant threshold was set up to maintain the False
discovery Rate (FDR) below 1 %. The identification was
done in duplicate, cutting bands and spot from replicate
gels. The results obtained for each identified protein are
listed in Table 1. Column 1 lists the protein entry names
according to the UniProt knowledge database, while the
others columns show the MS analysis data, such as the
ion scores (column 2), expressed as the probability that
the observed match between the experimental data and
the database sequence could be due to a random event;
queries (column 3), that is the total number of peptides
that matched the identified proteins and the significant
matches; the total number of sequences and the number
of significant sequences (column 4) and the sequence
coverage, namely the percentage of amino acids se-
quenced (final column).
Western blotting
In order to validate the results of electrophoresis (SDS-
PAGE e 2-DE) and precisely verify the identity of proteins
inferred from ESI-Q-ToF-MS analysis, we evaluated the
levels of PTGDS, UROM, AMBP and CYTC by Western
blot. The analysis was conducted with ten urine samples
for each group. As shown in Fig. 3a, PTGDS protein
Prostaglandin-H2 D-synthase
250-
150-
100-
75-
50-
37-
25-
20-
10-
M         1              2           3          4
Cystatin-C
Uromodulin
Alpha-1-microglobulin
Fig. 1 SDS-PAGE. The protein profiles were obtained from urine of
healthy controls (lane 1), triptans (lane 2), NSAIDs (lane 3), and
mixtures abusers (lane 4). M =molecular weight marker ladder
(DualColor, Bio-Rad). In box are evidenced the bands related to the
investigated proteins for each group. Poliacrylamide gel 12 % and
Coomassie blue staining
(c) AMBP
1 2 3 4
(d) CYTC
1 2 3 4
(b) UROM
1 2 3 4
(a) PTGDS
1 2 3 4
Fig. 2 Magnified spot section from 2D gel. Comparison of protein spot obtained by 2-DE analysis of urine samples from healthy controls (1), triptans
(2), NSAIDs (3), and mixtures abusers (4), for the four examined proteins: Prostaglandin-H2 D-synthase (a), Uromodulin (b), Aplha-1-microglobulin (c)
and Cystatin-C (d). For PTGDS protein was also reported the peack illustrating its relative abundance, obtained for each group by the PDQuest
software. First dimension was made with IPG strips 17 cm NL, pH 3-10; the second dimension was performed using 8-16 % polyacrylamide gradient
gels; 0.2 % silver nitrate was used for gel staining
Bellei et al. The Journal of Headache and Pain  (2015) 16:77 Page 4 of 9
was detected in all urine samples from every group, and
precisely was found to have higher levels in mixtures
(p = 0.001) and NSAIDs groups (p = 0.01), respect to
triptans abusers (p = 0.04), when compared vs healthy
controls, similarly to the results of 2-DE analysis.
UROM (Fig. 3b) showed a marked signal at 70 kDa and
a significant increase in all MOH patients compared to
control group. During Western Blot analysis, we used
human serum sample as control; regarding UROM,
since it is exclusively produced in the kidney and
secreted into the urine via proteolytic cleavage, no band
was observed at UROM molecular weight. Therefore,
serum sample can be considered as negative control,
while it represents a positive control for PTGDS,
AMBP and CYSC, that showed a clear signal; these 3
proteins, present in serum, are filtered by the kidney
and excreted in urine. AMBP signal (Fig. 3c) was highly
significant in all MOH abusers, particularly in NSAIDs
and mixtures groups (p = 0.0001 and p = 0.0005, re-
spectively) and also in triptans (p = 0.006) compared to
controls. Finally, the increase of CYTC (Fig. 3d) showed
its maximum signal in NSAIDs and mixtures abusers
(p = 0.001 and p = 0.04 vs control group), while triptans
group showed no significativity.
ELISA results
The expression level of PTGDS was estimated by
ELISA assay (Fig. 4). When compared to control
subjects, a significant increase in PTGDS immunoreac-
tivity was observed in all MOH patients groups.
Particularly, PTGDS level was highly significant in
mixtures (681 ± 218 ng/mL, p < 1.00E-06) and NSAIDs
Table 1 MS protein identification by ESI-Q-ToF-MS
Protein
namea
Scoreb N° matches/
sign.matchesc
N° seq./sign.seq.d Seq. cov.e
PTGDS 158 25/14 3/2 33 %
UROM 86 18/13 3/2 47 %
AMBP 201 21/12 4/3 32 %
CYTC 71 16/10 3/3 52 %
aProtein entry name (UniProt knowledge database)
bThe highest scores obtained using MASCOT search engine
cThe total number of peptides matched and the significant matches
dThe total number of sequences and the number of significant sequences
eSequence coverage: the percentage of amino acids sequenced for the
detected protein
31 kDa -
Ctrl       Trip    NSAIDs   Mix       Ctrl+
(c) AMBP
(d) CYSC
15 kDa -
Ctrl       Trip     NSAIDs   Mix      Ctrl+
0
2000
4000
Ctrl Trip NSAIDs Mix
28 kDa -
Ctrl        Trip     NSAIDs   Mix      Ctrl+    
(a) PTGDS
0
500
1000
1500
Ctrl Trip NSAIDs Mix
A
U
0
60
120
Ctrl Trip NSAIDs Mix
(b) UROM
70 kDa -
Ctrl         Trip      NSAIDs   Mix     Ctrl−
0
4000
8000
12000
16000
Ctrl Trip NSAIDs Mix
A
U
A
U
A
U
p=0.001
p=0.01
p=0.04
p=0.04
p=0.05
p=0.04
p=0.0005
p=0.0001
p=0.006
p=0.001
p=0.04
Fig. 3 Protein expression by Western blot. The analysis for each protein was conducted on urine samples from the four groups. Serum sample
was used as positive (or negative) control. The histograms show the quantitative representation of PTGDS (a), UROM (b), AMBP (c) and CYSC
(d) obtained by densitometric analysis with QuantityOne image analysis software (the data represent mean ± SD). Ctrl, healthy control group; Trip,
triptans abusers; NSAIDs abusers; Mix, mixtures abusers
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abusers (572 ± 135 ng/mL, p < 0.0001) in respect to
triptans abusers (450 ± 116 ng/mL, p < 0.01), when
compared to control group (303 ± 130 ng/mL). These
results are fully consistent with the data from 2-DE
(Fig. 2-a) and Western blot analysis (Fig. 3a). The mea-
sured values of urinary PTGDS fell on the linear por-
tion of the ELISA kit standard curve.
Discussion
In the present study we carried out additional analysis,
such as Western blot and ELISA assays, to validate our
previous findings aimed to discover early biomarkers of
drug-induced nephrotoxicity in MOH [8, 14], and to
enhance its accuracy of prediction. Among the differen-
tially expressed proteins previously identified, our study
focused on UROM, AMBP and CYSC, since an ample
literature provides evidence of their involvement in renal
damage and nephropathy. The special role played by
PTGDS, which is implicated in pain onset (particularly
CA), was also investigated [13]. CA is defined as pain in
response to non-nociceptive thermal and mechanical
stimuli applied to normal skin, a very uncomfortable
heightened sensitivity to touch [18, 19]. Some studies
indicated that up to 80 % of migraine patients reported
CA during an acute attack [6] or abnormal sensitivity of
extracranial areas [20]; others showed that most mi-
graine patients exhibit CA inside and outside their pain-
referred areas when examined during a fully developed
migraine attack [21]. CA in migraine is a clinical mani-
festation of central nervous system sensitization, and
consequently several chronic pain syndromes and mood
disorders are comorbid with migraine [22]. Given the
complexity of pain and its arduous and not particularly
effective treatment, there is an important need to define
who is susceptible to pain hypersensitivity, as well as to
discover new molecules and mechanisms finalized to the
identification of new therapeutic interventions with
greater efficacy. Studies has been recently carried out to
prove epigenetics role in the causation of chronic pain
[23], trying to clarify a pain-specific protein interaction
network [24, 25]. In the present study we focused on
PTGDS, also known as β-trace protein, a lipocalin-type
prostaglandin that is responsible for the conversion of
prostaglandin H2 (PGH2) into prostaglandin D2 (PGD2),
in the presence of sulfhydryl compounds [26]. PTGDS is
actively produced in a variety of tissues and is involved
in numerous physiological and pathological functions,
such as vasodilatation, inhibition of platelet aggregation
and nitric oxide release; moreover, it is a potent en-
dogenous nociceptive modulator [9]. Western blot ana-
lysis (Fig. 3a) and ELISA test (Fig. 4) lead to the
verification and validation of the proteomic data (Figs. 1
and 2-a), confirming that the MOH patients examined in
this work show an over-expression of urinary PTGDS,
especially NSAIDs and mixtures abusers, when compared
with triptans group and more vs healthy controls. On the
basis of these results, a clear indication arises directing to
the involvement of PTGDS in the manifestation of CA, by
decreasing pain threshold, as verified in MOH abusers
and in migraineurs patients recruited in a previous study
[27]. With the abuse of antimigraine drugs, migraineurs
patients may develop MOH, a frequent and disabling con-
dition characterized by increased headache frequency and
intensity, inefficacy of medications and development of
drug dependence [7]. Pain progression has been evaluated
in MOH patients, suggesting the presence of a global
alteration in the processing of noxious stimuli throughout
the pain matrix and the occurrence of significant
0
400
800
1200
Controls Triptans NSAIDs Mixtures
ng
/m
L
***
**
t-test vs controls: *p < 0.01; ** p< 0.0001; *** p< 1.00E-06
*
Fig. 4 Immunoreactivity of PTGDS by ELISA assay. Results are expressed as mean ± SD. Significant differences were assessed by unpaired
Student’t t-test (*p < 0.01; **p < 0.0001; ***p < 1.00E-06 vs control group)
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functional changes in the lateral pain pathway [28]. Only
by understanding the molecular circuits complexity and
the substances mediating pain, the development of in-
creasingly specific tools for the identification of new
markers, will be possible. In our study, MOH patients,
showing high levels of PTGDS, suffer pain growth and
progression, suggesting that PTGDS is indeed a potential
urinary biomarker indicating CA development. Different
types of prostaglandins play a key role in important
physiological conditions, such as renal function and devel-
opment. PTGDS is involved in the advancement of kidney
diseases, and has been proposed in the past years as a po-
tential diagnostic marker for renal injury [29]. Recently,
animal studies have shown that the urinary excretion of
PTGDS may predict the development of proteinuria and
renal injury [30]. In our study, an elevated PTGDS level
was determined in the urine of MOH patients (particu-
larly in NSAIDs and mixture abusers) (Figs. 2-a, 3a and 4),
suggesting the importance of monitoring MOH patients
renal function that, at its turn, will enable the prevention
of the drug-induced nephrotoxicity.
Other proteins involved in renal dysfunction, also
tested in this study, were UROM, AMBP and CYSC.
UROM (Tamm-Horsfall glycoprotein) is the most abun-
dant protein excreted in the urine under physiological
conditions, being exclusively synthesized by the cells of
the thick ascending limb and early distal convoluted
tubule of the kidney. UROM is produced in the endo-
plasmic reticulum, shuttled to the apical cell membrane,
and released into the urine by proteolytic cleavage [31].
UROM has been known for more than 50 years and
since its discovery several researches have been con-
ducted, revealing novel roles for this protein [32]. Re-
cently, genome-wide association studies identified UROM
as a risk factor for chronic kidney disease (CKD) and
hypertension, suggesting that the urinary level of UROM
represents a useful biomarker for the development and
progression of CDK [33, 34]. In our study, by Western
blot analysis we confirmed a significant over-excretion of
UROM (Fig. 3b) in all MOH patients compared to the
control group; the same was also observed for AMBP
(Fig. 3c). AMBP is a low molecular weight protein, also
called protein HC, which is readily filtered by the glom-
erulus and reabsorbed and catabolised by the proximal
tubular cells. Therefore, the presence of AMBP in urine is
indicative of reduced resorptive capacity of the proximal
tubule [35]; consequently, the urinary concentration of
AMBP, which is stable at low pH, designate this protein as
a useful marker of proximal tubular abnormalities and
chronic asymptomatic renal tubular dysfunction [36].
Moreover, urinary AMBP can be considered as a useful
marker for the early detection and monitoring of nephrop-
athy in type 2 diabetes [37]. Finally, we found a signifi-
cantly increased level of CYSC in NSAIDs and mixtures
abusers, but not in triptans abusers (Fig. 3d). Also CYSC
has been used for many years as a clinical marker of
kidney function [38]. This 15-kDa cysteine proteinase in-
hibitor is produced by all nucleated cells at a constant rate
and constitutively secreted shortly after its synthesis. Fol-
lowing glomerular filtration, CYSC is reabsorbed by the
proximal tubular cells, where it is almost completely catab-
olized, while the remaining uncatabolized protein is elimi-
nated in the urine [39]. Thus, normal urinary CYSC
concentration is very low, whereas in case of tubular dis-
eases CYSC degradation is reduced, leading to an increase
in its urinary elimination. Furthermore, a recent study re-
ported that urinary CYSC levels and tubular proteinuria
may predict the progression of type 2 diabetic nephropathy
[40]. Accumulating evidence suggests CYSC as a reliable
biomarker and predictor of impaired renal function, in
particular of tubular damage [41]. In summary, we have
now firmly established that PTGDS, UROM, AMBP and
CYSC are proteins over-excreted in the urine of MOH
patients, especially in NSAIDs and mixtures abusers,
compared to healthy non-abusers individuals.
The debate on the association between nonphenacetin-
containing combined analgesics and renal disease has
been going on for a long time. Some years ago, an inter-
national ad hoc peer-reviewed committee of scientists
concluded that there is no sufficient evidence to associate
nonphenacetin combined analgesics with nephropathy
[42]. A population-based case–control study with incident
cases of end-stage renal disease (ESRD) demonstrated that
the use of a high cumulative lifetime dose (3rd tertile) of
analgesics up to five years before dialysis was not associ-
ated with ESRD [43]. Others case-controls studies have
shown that caffeine-containing analgesics are associated
with analgesic nephropathy (odds ratio = 4.9, 95 % CI 2.3
to 10.3) [44]. In the series observed in our studies, we did
not register any case of clinical impairment of renal func-
tions. The main NSAIDs used were indomethacin, para-
cetamol and, in some cases, compounds containing
caffeine. However, if caffeine produces nephrotoxicity
on its own, or increases analgesics-related nephrotox-
icity is yet to be established [44]. In literature there is a
lack of definite data regarding causative analgesics,
including those concerning paracetamol. Hence, pa-
tients should not be withheld for paracetamol, an ef-
fective and commonly recommended agent, for fear of
worsening renal function [45], but, at the same time, an
increasing universal awareness about rational use of
analgesics is important for MOH prevention.
Conclusions
MOH has a prevalence of 1-2 % in the general population
worldwide and it is likely to be the most costly neuro-
logical disorder known [46]. Even more significantly,
MOH has similarities with traditional drug addiction.
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Nonetheless, there is a lack of research into awareness,
education and prevention of MOH [47, 48]. With the
present work we firmly confirmed and strengthen our
previous findings regarding the possibility of drug-induced
nephrotoxicity in MOH patients, particularly in the case
of NSAIDs and mixtures abuse. These results contribute
to emphasize the importance in providing educational and
preventive strategies concerning the risks linked to MOH,
such as the probability of developing renal injuries. There-
fore, the proteins under our scrutiny may represent a
reliable and distinctive panel of prospective early target of
kidney dysfunctions, useful to monitor over time renal
function of MOH abusers, recognizing patients prone to
progress toward nephropathy. Accordingly, these findings
could enhance the awareness about the risks associated to
MOH, helping to reduce morbidity. Moreover, the present
results on PTGDS may be useful to provide a common
target for advanced study, aimed to analyze pain mecha-
nisms and pathways at the molecular level, particularly in
the case of CA. The increase of urinary PTGDS observed
also in patients taking triptans could be an early indicator
of a nervous system driven up-regulation associated to
chronic pain, as in the case of MOH. Even if there are no
conclusive data showing a direct impact of NSAIDs on
kidney functions in headache patients, these findings
could represent an initial marker linked to a specific type
of pain, such as CA.
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